...Vienna, Austria Business: Infectious, Inflammation Hired: Angelika Bodenteich as head of development, formerly CMO of onepharm Research & Development GmbH WIR...

...glycyrrhizin derivatives from onepharm Research & Development GmbH , which spun out its influenza assets into Savira in 2009. onepharm...
...Institutions Mentioned European Molecular Biology Laboratory (EMBL), Heidelberg, Germany Fujifilm Holdings Corp. (Tokyo:4901), Tokyo, Japan onepharm Research & Development GmbH...
...Disease focus: Infectious Clinical status: Preclinical Founded: 2009 by European Molecular Biology Laboratory (EMBL) and onepharm Research & Development GmbH...

...Wuhan has completed preclinical testing of the small molecule against an undisclosed target for IBD. onepharm...
...start Phase I testing in 1H10. Wuhan is eligible for undisclosed milestones and single-digit royalties. onepharm Research & Development GmbH...

...I trial by year end. Financial terms were not disclosed. Bionetworks GmbH , Munich, Germany onepharm Research & Development GmbH...

...to develop and market Minophagen's OPM-3001 in Europe and the U.S. to treat influenza infection. onepharm...
...eligible for royalties and will retain rights to market OPM-3001 for influenza in Asia, where onepharm...
...root, to treat chronic HCV infection in Asia. Minophagen Pharmaceutical Co. Ltd. , Tokyo, Japan onepharm Research & Development GmbH...